Quantum Genomics (PAR: ALQGC)

Last close As at 21/12/2024

0.17

0.00 (2.35%)

Market capitalisation

EUR6m

Quantum Genomics is a biopharmaceutical company developing firibastat, a brain aminopeptidase A inhibitor for the treatment of hypertension and heart failure. Its mechanism is implicated in the 25% of patients resistant to treatment. The Phase IIb study in hypertension was recently very positive and the Phase IIb in heart failure should start in Q219.

Latest Insights

View More

Healthcare | Flash note

Quantum Genomics — Firibastat misses endpoints in Phase III

Healthcare | Initiation

Quantum Genomics — A fresh take on cardiovascular medicine

Healthcare | Update

Quantum Genomics — Phase IIb QUORUM results

Thematics

thematic

Borussia Dortmund – executive interviews

thematic

UK equities: A generational opportunity?

thematic

Energy & Resources

Renewable energy developers – Creating value for investors

thematic

Healthcare

Healthcare-focused trusts: A sector on the mend

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free